The Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR (levocetirizine dihydrochloride; Sanofi) tablets and oral solution as over-the-counter (OTC) treatments for the relief of symptoms associated with seasonal and year-round allergies.
The Xyzal Allergy 24HR tablets are intended for use in patients aged ≥6 years. The Xyzal Allergy 24HR oral solution is intended for use in patients aged ≥2 years. A single daily dose is intended to provide 24-hour symptom relief.
The principal effects of Xyzal, an antihistamine, are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models.
Xyzal Allergy 24HR will be available as 5mg strength tablets and as a 0.5mg/mL oral solution. Both products are expected to launch in Spring 2017.
For more information call (800) 446-6267 or visit sanofi-aventis.us.